INND (Innerscope Hearing Technologies) Earnings Yield (Joel Greenblatt) %: 0.00% (As of Dec. 2020)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innerscope Hearing Technologies Earnings Yield (Joel Greenblatt) %?

Innerscope Hearing Technologies INND -99.00% Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2020.

Innerscope Hearing Technologies's Enterprise Value for the quarter that ended in Dec. 2020 was $6.19 Mil. Innerscope Hearing Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $-3.85 Mil. Innerscope Hearing Technologies's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2020 was 0.00%.

The historical rank and industry rank for Innerscope Hearing Technologies's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

INND's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.98
* Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Innerscope Hearing Technologies's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2020 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Innerscope Hearing Technologies  (OTCPK:INND) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Innerscope Hearing Technologies Earnings Yield (Joel Greenblatt) % Related Terms


Innerscope Hearing Technologies Earnings Yield (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Innerscope Hearing Technologies's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innerscope Hearing Technologies Earnings Yield (Joel Greenblatt) % Chart

Innerscope Hearing Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial 0.00 -27.78 -95.24 -93.46 -53.76

Innerscope Hearing Technologies Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

INND vs NWCN, NCAP, MOBQ: Earnings Yield (Joel Greenblatt) % Comparison

For the Medical Instruments & Supplies subindustry, Innerscope Hearing Technologies's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innerscope Hearing Technologies Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Innerscope Hearing Technologies's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Innerscope Hearing Technologies's Earnings Yield (Joel Greenblatt) % falls into.



Innerscope Hearing Technologies Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Innerscope Hearing Technologiess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2020 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-3.242/6.026
=-53.80 %

Innerscope Hearing Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.85 Mil.


What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Innerscope Hearing Technologies (INND) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Dec. 2020. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Innerscope Hearing Technologies and its competitors.
Is Innerscope Hearing Technologies' Earnings Yield (Joel Greenblatt) % too high?
Innerscope Hearing Technologies' current Earnings Yield (Joel Greenblatt) % is 0.00%.
How does Innerscope Hearing Technologies' Earnings Yield (Joel Greenblatt) % compare to NWCN and NCAP?
Innerscope Hearing Technologies' Earnings Yield (Joel Greenblatt) % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.98, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Innerscope Hearing Technologies and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innerscope Hearing Technologies's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innerscope Hearing Technologies stock overvalued right now?
Innerscope Hearing Technologies (INND) has a current Earnings Yield (Joel Greenblatt) % of 0.00%. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Innerscope Hearing Technologies (INND), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innerscope Hearing Technologies Business Description

Address 2151 Professional Drive, Suite 105, Roseville, CA, USA, 95661
Innerscope Hearing Technologies Inc is a manufacturer and distributor of OTC Hearing Aids, Hearing Aid Accessories & Hearing Health-Related Products (Hearing Products) dedicated to addressing the demand for affordable hearing solutions. The company operates retail hearing device clinics in California. InnerScope is focused on leveraging these strategic assets to identify, incubate, and support health-technology ventures positioned for growth in public markets and long-term shareholder value creation.